CYAD-01 without preconditioning chemotherapy was well-tolerated and demonstrated anti-leukemic activity in five out of eight (62%) evaluable patients with relapsed or refractory (r/r) acute myeloid ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback